← Back to home

INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY

Clinical trials for INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY explained in plain language.

Never miss a new study

Get alerted when new INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY trials appear

Sign up with your email to follow new studies for INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug combo aims to help myelofibrosis patients who struggle with current treatments

Disease control Ongoing

This study is testing whether adding a new drug called WJ01024 to an existing medication (ruxolitinib) can help people with intermediate- or high-risk myelofibrosis, especially those whose disease hasn't responded well to prior JAK inhibitor treatments. The main goals are to see …

Matched conditions: INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY

Phase: PHASE1, PHASE2 • Sponsor: Suzhou Junjing BioSciences Co., Ltd. • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY

Get alerted when new INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY trials appear

New drug combo aims to help myelofibrosis patients who struggle with current treatments